Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with concurrent chemoradiotherapy for advanced lung or esophageal cancer with multiple lymph node metastases
ChiCTR2400082732Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in bronchial carcinoma and esophageal cancer (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Lymph node target lesion objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
bronchial carcinomaesophageal cancer
Beyond the preview
Go deeper on ChiCTR2400082732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082732.